Patent intelligence · US
US 11426418
Injectable long-acting semi-solid gel formulations
Injectable long-acting semi-solid gel formulations
Patent details — US 11426418
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 30, 2022
- Expiration
- Aug 25, 2042
- Applicant
- MIRA PHARMA CORPORATION
- Claims
- 20
- CPC classes
- A61K, A61K31/231, A61K31/415, A61K31/5575
Quick answer
US 11426418 (Injectable long-acting semi-solid gel formulations) is held by MIRA PHARMA CORPORATION. Status: granted. Granted Aug 30, 2022. Expires Aug 25, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MIRA PHARMA CORPORATION
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/231, A61K31/415, A61K31/5575, A61K31/56, A61K31/573
More from MIRA PHARMA CORPORATION
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 11426418?
US 11426418 (Injectable long-acting semi-solid gel formulations) is held by MIRA PHARMA CORPORATION. Status: granted. Granted Aug 30, 2022. Expires Aug 25, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11426418?
MIRA PHARMA CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 11426418 expire?
Our index shows an expiration date of Aug 25, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.